Malgorzata Lipowska1, Nashwa Jarkas2, Ronald J Voll3, Jonathon A Nye3, Jeffrey Klenc2, Mark M Goodman3, Andrew T Taylor2. 1. Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. Electronic address: mlipows@emory.edu. 2. Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. 3. Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, NE, Atlanta, GA 30322, USA; Center for Systems Imaging, Emory University, Wesley Woods Health Center, 1841 Clifton Road, NE, Atlanta, GA 30329, USA.
Abstract
INTRODUCTION: Our previous work demonstrated that the 99mTc renal tracer, 99mTc(CO)3(FEDA) (99mTc-1), has a rapid clearance comparable in rats to that of 131I-OIH, the radioactive gold standard for the measurement of effective renal plasma flow. The uncharged fluoroethyl pendant group of 99mTc-1 provides a route to the synthesis of a structurally analogous rhenium-tricarbonyl 18F renal imaging agent, Re(CO)3([18F]FEDA) (18F-1). Our goal was to develop an efficient one-step method for the preparation of 18F-1 and to compare its pharmacokinetic properties with those of 131I-OIH in rats. METHODS: 18F-1 was prepared by the nucleophilic 18F-fluorination of its tosyl precursor. The labeled compound was isolated by HPLC and subsequently evaluated in Sprague-Dawley rats using 131I-OIH as an internal control and by dynamic PET/CT imaging. Plasma protein binding (PPB) and erythrocyte uptake (RCB) were determined and the urine was analyzed for metabolites. RESULTS: 18F-1 was efficiently prepared as a single species with high radiochemical purity (>99%) and it displayed high radiochemical stability in vitro and in vivo. PPB was 87% and RCB was 21%. Biodistribution studies confirmed rapid renal extraction and high specificity for renal excretion, comparable to that of 131I-OIH, with minimal hepatic/gastrointestinal elimination. The activity in the urine, as a percentage of 131I-OIH, was 92% and 95% at 10 and 60 min, respectively. All other organs (heart, spleen, lungs) showed a negligible tracer uptake (<0.4% ID). Dynamic microPET/CT imaging demonstrated rapid transit of 18F-1 through the kidneys and into the bladder; there was no demonstrable activity in bone verifying the absence of free [18F]fluoride. CONCLUSIONS: 18F-1 exhibited a high specificity for the kidney, rapid renal excretion comparable to that of 131I-OIH and high in vivo radiochemical stability. Not only is 18F-1 a promising PET renal tracer, but it provides a route to the development of a pair of analogous 18F/99mTc renal imaging agents with almost identical structures and comparable pharmacokinetic properties. These promising in vivo results warrant subsequent evaluation in humans.
INTRODUCTION: Our previous work demonstrated that the 99mTc renal tracer, 99mTc(CO)3(FEDA) (99mTc-1), has a rapid clearance comparable in rats to that of 131I-OIH, the radioactive gold standard for the measurement of effective renal plasma flow. The uncharged fluoroethyl pendant group of 99mTc-1 provides a route to the synthesis of a structurally analogous rhenium-tricarbonyl 18F renal imaging agent, Re(CO)3([18F]FEDA) (18F-1). Our goal was to develop an efficient one-step method for the preparation of 18F-1 and to compare its pharmacokinetic properties with those of 131I-OIH in rats. METHODS: 18F-1 was prepared by the nucleophilic 18F-fluorination of its tosyl precursor. The labeled compound was isolated by HPLC and subsequently evaluated in Sprague-Dawley rats using 131I-OIH as an internal control and by dynamic PET/CT imaging. Plasma protein binding (PPB) and erythrocyte uptake (RCB) were determined and the urine was analyzed for metabolites. RESULTS: 18F-1 was efficiently prepared as a single species with high radiochemical purity (>99%) and it displayed high radiochemical stability in vitro and in vivo. PPB was 87% and RCB was 21%. Biodistribution studies confirmed rapid renal extraction and high specificity for renal excretion, comparable to that of 131I-OIH, with minimal hepatic/gastrointestinal elimination. The activity in the urine, as a percentage of 131I-OIH, was 92% and 95% at 10 and 60 min, respectively. All other organs (heart, spleen, lungs) showed a negligible tracer uptake (<0.4% ID). Dynamic microPET/CT imaging demonstrated rapid transit of 18F-1 through the kidneys and into the bladder; there was no demonstrable activity in bone verifying the absence of free [18F]fluoride. CONCLUSIONS: 18F-1 exhibited a high specificity for the kidney, rapid renal excretion comparable to that of 131I-OIH and high in vivo radiochemical stability. Not only is 18F-1 a promising PET renal tracer, but it provides a route to the development of a pair of analogous 18F/99mTc renal imaging agents with almost identical structures and comparable pharmacokinetic properties. These promising in vivo results warrant subsequent evaluation in humans.
Authors: Fabio P Esteves; Andrew Taylor; Amita Manatunga; Russell D Folks; Meghna Krishnan; Ernest V Garcia Journal: AJR Am J Roentgenol Date: 2006-12 Impact factor: 3.959
Authors: Malgorzata Lipowska; Haiyang He; Xiaolong Xu; Andrew T Taylor; Patricia A Marzilli; Luigi G Marzilli Journal: Inorg Chem Date: 2010-04-05 Impact factor: 5.165
Authors: Malgorzata Lipowska; Jeffrey Klenc; Nashwa Jarkas; Luigi G Marzilli; Andrew T Taylor Journal: Nucl Med Biol Date: 2016-12-27 Impact factor: 2.408
Authors: Rudolf A Werner; Xinyu Chen; Constantin Lapa; Kazuhiro Koshino; Steven P Rowe; Martin G Pomper; Mehrbod S Javadi; Takahiro Higuchi Journal: Eur J Nucl Med Mol Imaging Date: 2019-05-30 Impact factor: 9.236
Authors: Zhengtao Qin; Carl K Hoh; Emilia S Olson; Amin Haghighat Jahromi; David J Hall; Christopher V Barback; Young-Hyun You; Motoko Yanagita; Kumar Sharma; David R Vera Journal: J Nucl Med Date: 2019-02-22 Impact factor: 10.057
Authors: Camilo A Ruiz-Bedoya; Alvaro A Ordonez; Rudolf A Werner; Donika Plyku; Mariah H Klunk; Jeff Leal; Wojciech G Lesniak; Daniel P Holt; Robert F Dannals; Takahiro Higuchi; Steven P Rowe; Sanjay K Jain Journal: J Nucl Med Date: 2020-03-20 Impact factor: 11.082